Heim N, et al. - An exploration was carried out of the impact of antiresorptive medication (AM) in the treatment of bone-affecting cancer-related conditions and osteoporosis, which presented as osteonecrosis of the jaw (ONJ). The data exhibited a possible rise in the prevalence of MRONJ in AM treated patients, by low serum vitamin D (25-OHD). A measurable tendency in the role of 25-OHD for the development of MRONJ was recorded. It assisted in the recommendation for a sufficient vitamin D substitution in patients treated with AM.